ICER Review Of NSCLC Drugs To Include Roche’s Pending Indication For Tecentriq
This article was originally published in The Pink Sheet Daily
Executive Summary
Institute for Clinical and Economic Review aims to complete cost effectiveness analysis of non-small lung cancer drugs in time for supplemental approval of the newest PD-L1 inhibitor in the space.
You may also be interested in...
ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer
ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.
Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines
Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: